Leading academicians, gathered!China's first MET Summit Forum was held simultaneously in five places across the country.

Author:Cancer Channel of the Medical Time:2022.08.01

*For medical professionals for reading reference

The first MET Summit Forum of "One Pulse inheritance Zhiyu Future".

As China ’s first and only high -selective MET inhibitors in June 2021 were approved for listing, China opened the first year of MET, and MET diagnosis and treatment ushered in a rapid development. On the first anniversary of the listing of Saivinib, on July 30, 2022, the "One Pulse MET Mets inheritance Smart Luming Future -the First MET Summit Forum" hosted by the China Health Promotion Foundation " The five places in Nanjing and Chengdu were grandly held.

This meeting invited a number of big coffees and young and middle -aged experts in the field of tumor fields to conduct academic sharing and clinical discussions. From current progress to future goals, comprehensive interpretation of hot topics such as drug research and development, precision testing, treatment selection, cutting -edge research on MET pathways, etc. And share the practical experience in clinical diagnosis and treatment, and discuss the precise treatment and cutting -edge progress of the MET pathway.

Launching Ceremony

Nanjing venue, Shanghai venue

Guangzhou venue, online venue

Excellence group-MET abnormal tumor precise treatment

At the beginning of the meeting, the chairman of the conference, Professor Lu Shun, Professor Shen Lin, Academician Yu Jinming, Professor Wang Changli, Professor Cheng Ying, Professor Wang Jie, Professor Wu Yilong, and other warm congratulations to the first anniversary of the listing of Saivotinib! It means that the success of Savacibilian to create the first year of Chinese MET inhibitors. In the past year, for patients, the clinical medication of Savidi has improved the survival prognosis of patients with MET mutant lung cancer, allowing more Chinese patients to see the opportunities and dawn of treatment. For doctors, Savacini provides more patients with different MET variation -related treatment needs in clinical clinical clinical options, breaking the predicament of previous no medicine. The approval of the domestic original research and innovation medicine Saivinib was listed, which is exactly the true practice of "medicine can be medical, good medicine can be available" concept.

Professor Lu Shun, Professor Shen Lin, Professor Wang Changli, Academician Yu Jinming, Professor Cheng Ying, Professor Wang Jie, and Professor Wu Yilong (from top to bottom, from left to right)

Mr. Chen Kangwei, general manager of Astraikon China Tumor Division, delivered a speech: It coincides with the first anniversary of the listing of Saivinib, and sincerely thank Professor Lu Shun's team and many Chinese experts for their hard work. As China's first MET inhibitor, Savidi not only successfully filled the gap in domestic MET inhibitors, but also showed China's continuous improvement of innovative drug research and development capabilities worldwide. I remember Professor Lu Shun shared the treatment experience of the first participation in the Syverninib registered clinical research subjects. Since he participated in clinical research in 2017, he still received the treatment of Savaci today. The survival period has exceeded 5 years. People are touched and encouraged. Astraco is also conducting more diagnosis and treatment explorations related to MET pathways, in order to make more MET mutant patients achieve long -term benefits. Here, we call for and look forward to the support of experts, so that Savacinib can successfully enter the national medical insurance negotiations this year, so that the local original drugs can benefit more than how many patients with lung cancer.

Mr. Chen Kangwei

During the same period of the conference, 12 media and other media such as Shanghai Television, China News Agency, Xinhua News Agency, Wen Bao, Xinmin Evening News, News Morning News, Health Times and other media interviewed Professor Lu Shun, Dr. Su Xunguo, and Mr. Chen Kangwei. Professor Lu Shun Call for Savitinib to be included in the field of medical insurance as soon as possible to help patients realize "medicine can be medicine, good medicine can be achieved"! Enterprises also wish local innovative drugs to "go out to the sea" as soon as possible to allow the world to experience the power of "China’ s intelligence manufacturing ". International giants and local pharmaceutical companies have jointly achieved an incremental effect of 1+1> 2!

Multiple media interviews

Gaowu Jianyu-From R & D to clinical, big coffee talks with accurate treatment of lung cancer

Academician Chen Kaixian of the Chinese Academy of Sciences introduced the new opportunities and new challenges faced by my country's scientific and technological innovation. With the development of major special projects of "major new drugs", my country's drug research and development have made great progress. Dr. Su Weuo, CEO of Huang, introduced the progress of clinical projects in research on non -small cell lung cancer (NSCLC), gastric cancer, nipple kidney cancer and other fields in non -small cell lung cancer (NSCLC).

Academician Chen Kai, Academician Su Shi Guo

In the "Peak Pickup" academic sharing session, Professor Dong Xiaorong first affirmed the good tumor response efficacy data obtained by the Saverninib outside Met14, which was obtained from the MET14. The difficult people in the inside show the breakthrough effect. On the other hand, for the NSCLC EGFR-TKIS drug resistance, MET amplification/over-expression dual-drive dual-precision combined treatment schemes have also been preliminarily verified. Saffron studied the Global III Studies led by Chinese experts. It is believed that in the clinical exploration led by the Chinese expert team, Savacinib is expected to achieve global curve overtaking in the field of MET amplification.

Professor Dong Xiaorong

Later, Professor Lu Shun led everyone to interpretation of clinical efficacy, general survival (OS) data interpretation, clinical diagnosis and treatment options for people who could not cure, EGFR-TKI drug resistance, MET expressed the treatment plan for patients, MET immunohistochemistry (IHC) threshold standards and other topics. In -depth exchanges, discussing the guests expressed their opinions, and kept it eagerly.

Professor Fan Yan said that in the past, there was a controversy with whether the jumping mutation of Met14 outer14 was a carcinogenic driver gene. The release of the efficacy data in the research data in high selective MET-TKI studies such as Savinininib confirmed its patients to patients. The importance of driving characteristics. For the timing of local treatment of lung cancer brain metastasis with jumping and mutations from MET14, combined with guidelines recommendation and personal clinical experience, if brain metastases have obvious symptoms, at the same time, targeted therapy and local treatment may improve benefits; if the symptoms of brain metastases have obtained the symptoms Control, delaying local treatment is also feasible. Professor Ai Xinghao pointed out that in the real world, the clinical characteristics of the clinical characteristics of the NSCLC patients in China and the United States Met14 are basically the same. However, there are no differences in the incidence of brain metastasis and liver metastasis in the United States or not with MET14 outer 14. The incidence of liver metastases is not different, and patients with jumping mutations in China MET14 are more likely to have adrenal metastases. In addition, the real world of American real world found that PD-L1 high expression in patients with out-of-reveal sub-jump mutations in MET14 accounted for a relatively high proportion of high tumor mutation load (TMB).

Professor Yao Yu said that although Savatinin has not been approved for first -line treatment, due to chemotherapy and immunotherapy MET14, the late NSCLC efficacy of the late -stage jump mutation is limited, and although the clinical study of Savidinini has been entered into a high proportion of lungs, which has a high proportion of lungs. Sabble -like cancer (PSC), brain metastases, and old age, but still obtained good OS, no progressive survival (PFS), and objective relief rate (ORR) data. Therefore, targeted therapy should be used as such patients The first -line preferred plan.

Professor Yu Yan shared that the results of TATTON research showed that Saverninib+Oshitinib was expanded/expressed in the EGFR-TKI resistance after EGFR-TKI. Safety of control. In clinical practice, patients with ≥ 5 after EGFR-TKI are resistant to MET, if economic conditions permit, it is feasible to try to use Savininib+Oshitinib.

Professor Yang Yanji pointed out that in the clinical study of EGFR-TKI resistance, MET amplification/over-expression patients' entry standards are very chaotic and still lack a unified definition. Judging from the preliminary results of Savannah's research, the higher the level of MET's expression, the efficiency of the combined treatment of dual targets also increases. For patients with metaphysics that guide clinical treatment, IHC testing patients with 3+ tumor cells 3+, dual -target combined treatment may have prospects.

The discussion session Shanghai venue, discussion session online meeting

Combined vertical-MET abnormal tumor precision diagnosis and treatment future prospects

The chairman of the branch venues and the host of the manuscript

This link is held in five places in Shanghai, Beijing, Guangzhou, Nanjing, and Chengdu. Experts and scholars at the five branch venues focus on "Dianshi Gold-Exploration of the Primary Met Met abnormal lung cancer", "The Clinical Practical Experience Sharing of Clinical Practice of Met abnormal lung cancer diagnosis and treatment" "Reaction Management", "More than-MET-TKI in the R & D layout of full cancer," and conducted a warm discussion.

Dianshi Gold -Exploration of Primary Met Met abnormal lung cancer

EGFR mutations accompanied by the original MET amplification/expressed advanced NSCLC patients received the prognosis of EGFR-TKI single drug treatment in front line. MET-TKI combined with EGFR-TKI can also block EGFR and MET signaling pathways at the same time, dual-drive dual precision treatment It may be possible; and in retrospective research and small sample analysis, MET-TKI and EGFR-TKI combined treatment shows the potential for first-line therapy. At present, the first -line treatment of EGFR mutations with Oshitinib for the first -line Olivininib to accompany the primary MET amplification/overplay the advanced NSCLC phase II FLOWERS research and III phase Sanovo research is in progress, and the results are worth looking forward to; at the same time, more The joint treatment plan is also being explored.

For EGFR wild type accompaniment MET amplification/over -expression, the efficacy of MET inhibitors single drug treatment is limited. CAPMATINIB+Nawli Ulitabi treats the EGFR wild type combined MET abnormal late NSCLC patients observed the trend of survival benefits, but the sample volume is limited. Therefore, whether MET-TKI combined with immunotherapy can be the EGFR wild type accompanying MET amplification/ Patients with late NSCLC have brought better long -term benefits and still need to be further studied in large samples. At present, the clinical study of Savidininib combined with Dagatabi treatment of EGFR wild -type accompanying MET abnormal late NSCLC is underway.

Speaker of each branch venue

Clinical practical experience sharing of clinical practice experience of metal abnormal lung cancer diagnosis and treatment

The report first shared a Cywotinib case: left lung adenocarcinoma with a variety of internal interior and left pulp lymph nodes, brain, and whole body bone migration (CT4N2M1C IVB period), MET14 outer sub-jump jump mutation, PD-L1 high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, high expression, ECOG 1 point. The first -tier Paborizumab was treated with new intracranial lesions and the progress of the disease after 3 months; the second -line Savotinib was treated with a target lesion by 60%, reaching partial relief, and the brain lesions remained stable. So far, PFS is 7 months.

In China's registered research on the MET14 outer 14 out -of -the -art child jumping mutation NSCLC, the treatment of Savitinib showed good and lasting tumor relief, Orr reached 49.2%, and the disease control rate (DCR) reached 93.4%. In addition, the baseline with a brain metastases to be treated or maintained in the intracranial lesions after Saivininib was treated, reminding that Savacinib can penetrate the blood -brain barrier and control the brain lesions well. In addition, for patients with high-expanded PD-L1 high-expressed in MET14, the preface and reasonable use of multiple drugs are the key to achieving long survival, but the best treatment order still needs to be discussed. Speaker of each branch venue

Copy calm-MET-TKI adverse reaction management

Common common adverse reactions of MET-TKI include peripheral edema, nausea and vomiting, and liver toxicity. Fully understand, actively prevent, correctly identify, and reasonably respond to adverse drug reactions, which will help improve patients' treatment compliance and tolerance, improve the quality of life, and are expected to extend their survival time.

Among them, peripheral edema is mostly level 1-2, and the response strategy includes: monitoring as soon as possible (such as weight), lifestyle intervention (restricting salt intake, adding exercise when symptoms occur or exercise accordingly) Wearing elastic socks and lymph massage), monitoring the skin (avoid lesions), and diuretics and glucocorticoids.

Most of the nausea and vomiting are mild, and the response strategies include: health education and strict observation, lifestyle management (eat less meals, choose easy to digest, coincide with appetite, control the amount of food, avoid eating spicy and irritating foods, not eating cold or hot foods. Wait), drug prevention and drug intervention. For nausea and vomiting drug intervention caused by MET-TKI, the two-united or three-united scheme is rarely used. Most patients can improve with 5-HT3 receptor antagonists.

Hepatic toxicity is mostly milder (level 1 to 2) and reversible. Patients with non -symptoms do not need to reduce or interrupt the treatment. If it is ≥ 3 drug -based liver injury, if the danger of the stopping drug is greater than the continued medication, the drug should be tried to reduce or suspend the medicine. After the adverse reactions are reduced or returned to normal, they should start using the medicine carefully. Hepatitis biochemical indicators and other changes. If there are serious situations such as Alt/AST & 8 ULN, the drug should be considered.

Speaker of each branch venue

Seeking more than-MET-TKI in the development and development layout of full cancer

In solid tumors, the exploration of various MET inhibitors is in full swing. Among them, Savetinib is brave to explore. There are 8 stages of phase III registered in other physical tumors (gastric cancer, kidney cancer, etc.). Lead other MET-TKI.

In the pre -clinical study in 2015, Savininib showed obvious anti -tumor activity in the MET amplified gastric cancer -derived tumor -transplanted tumor model, indicating that it has potential treatment potential for MET amplification gastric cancer. In Viktory, a phase II umbrella -type umbrella -type umbrella -type umbrella -type umbrella in South Korea in 2019, the ORR of Savidi Pharmaceutical Second Treatment MET to enlarged advanced gastric cancer was 50%(the study assumes that traditional second -line treatment ORR is 20%). Saivinib single drugs in advanced gastric cancer patients in MET amplification are in progress and are expected to be expected in the future.

In addition, the efficacy of Savidi -based drug/combined treatment of advanced papillary renal cell carcinoma driven by MET is encouraged. The results of the Savoir study showed that the ORR of the advanced papillary renal cell carcinoma driven by Savidoni single drugs was 27 % and the median PFS was 7.0 months; compared to the treatment of Schoninib, it showed a better effect. Benefits and security. At present, Saavininib combined with the first -line treatment of advanced papillary renal cell carcinoma driven by MET -driven MET -driven Global III Clinical Research (SameTa) is underway, and the results are worth looking forward to.

Speaker of each branch venue

Wisdom-Eye Consciousness-Precision MET detection will help precise treatment

This link is also held in five places in Shanghai, Beijing, Guangzhou, Nanjing, and Chengdu. Experts and scholars at the five branch venues have carried out "Optimization of MET Testing Technology from Clinical Practice" "Optimization of MET Detection Technology", "Optimization of MET Detection Technology", "Seeing the Road to Optimization and Optimization of Quality Control Management from Lung Cancer Single Diseases", And conduct warm discussions.

Preface to Qiankun -Optimization of MET detection technology from clinical practice

MET14 outer exposure jump mutation is a required examination gene recommended by the guide, but clinical testing practice still needs to be improved. It is recommended that clinical practice includes polynoma joint inspections including MET No. 14 outer sub -jump mutations. The second-generation sequencing (NGS) and the reversal quantitative polymerase chain reaction (RT-QPCR) are the commonly used MET14 outer-jump mutation detection methods commonly used in clinical. A variety of optimization strategies can help improve detection efficiency and accuracy. A variety of methods such as fluorescent in situ hybridization (FISH), NGS, and micro -drop digital polymerase chain reactions (DDPCR) can be used for MET amplification detection. Among them, FISH is the gold standard for detecting MET amplification. NGS still needs to explore tumor cells The average gene copy number (GCN) conversion and reported multi -body. IHC is a commonly used MET protein expression detection method, which can be performed in clinical practice.

Beyond Following Following Following the Path from the Massage Control Management of Lung -Cancer Single Diseases

my country's cancer burden is heavy, which poses a serious threat to the public and society, especially lung cancer, and the prevalence and mortality rate of the prevalence and mortality are first. Its diagnosis and treatment specifications must attract great attention. With the development of precision medicine, the quality control management needs of tumors, especially lung cancer, have become more urgent, and the state has launched a number of measures to promote the formulation and implementation of the quality control of tumor single disease. In the practice of tumor diagnosis and treatment control management, it is still necessary to actively improve the quality control items and standards covering the people of different patients, as well as the quality control items and standards of various diagnosis and treatment links. Driven gene state is the basis for establishing targeted therapy strategies. NSCLC quality control, such as BRAF, MET, ROS1, RET, etc., is also not ignored. Strict quality control must be performed to further improve the patient's fine division and diagnosis specifications. Speaker of each branch venue

Conference summary

The conference ended in a strong academic atmosphere. Although MET is a rare target, considering that the number of malignant tumors in my country is huge, MET abnormalities can occur in different cancers such as lung cancer, gastric cancer, and kidney cancer. Therefore, there are many patients with MET abnormal tumors in my country. In the past, MET abnormal tumor patients lacked high -selective targeted therapy, and the emergence of high -selective MET inhibitors Savinib provided new treatment options for such patients, becoming a rare target innovative drug in China, becoming a rare target innovative drug for innovative drugs in China Important benchmark. Experts have unanimously called on Saivinib to be included in the national medical insurance catalog as soon as possible to help patients realize "medicine can be medical, good medicine!"